How do I install the Enda Dhea Trial Women Symptoms skill?

Run npx skillmds@latest add dromlakhani/enda-dhea-trial-women-symptoms in your terminal (requires Node.js), paste this page's agent-chat prompt into Claude, Cursor, or any MCP-connected agent, or download the SKILL.md file and copy it into your agent's skills directory.

Is Enda Dhea Trial Women Symptoms safe to use?

This skill has not completed SkillMD's automated safety review yet. Independent scanners report: SkillSpector: PASS, Skill Scanner: PASS. Capability flags: docs only. SkillMD never runs a skill's scripts for you; review the SKILL.md before installing.

Which AI agents work with Enda Dhea Trial Women Symptoms?

This skill is tagged as working with Claude Code, Claude.ai, OpenAI Codex. SKILL.md is an open format, so most agents that read a skills directory can load it too.

Is Enda Dhea Trial Women Symptoms free to use?

Yes. Installing skills from SkillMD is free, and the skill stays under its author's original license.

Who published Enda Dhea Trial Women Symptoms?

dromlakhani (@dromlakhani) published this skill. Their other Agent Skills are listed on their SkillMD profile.

Enda Dhea Trial Women Symptoms by dromlakhani

Name: Enda Dhea Trial Women Symptoms
Rating: 4.2 (5 reviews)
Author: dromlakhani

Enda Dhea Trial Women Symptoms

Suggests a trial of dehydroepiandrosterone (DHEA) replacement in women with primary adrenal insufficiency (PAI) who report low libido, depressive symptoms, and/or low energy levels despite otherwise optimized glucocorticoid and mineralocorticoid replacement. Consider when a woman with PAI presents with persistent low libido, depressive symptoms, and/or low energy levels after glucocorticoid and mineralocorticoid doses have been titrated to clinical targets.

dromlakhani Updated Sep 8, 2026 10 repo stars

File contents

Trial DHEA Replacement in Women with PAI and Specific Symptoms

STEP 1 — Gather Information

Confirm PAI diagnosis, review current glucocorticoid (e.g., hydrocortisone 15–25 mg/day) and mineralocorticoid (fludrocortisone 50–100 µg/day) doses, assess for clinical signs of over- or under-replacement (weight, BP, electrolytes), and document presence of low libido, depressive symptoms, and/or low energy levels.

STEP 2 — Rule In / Rule Out

Determine whether symptoms persist despite optimized steroid replacement; if yes, proceed to DHEA trial consideration, otherwise evaluate for other causes of fatigue or low libido (e.g., thyroid dysfunction, depression, anemia).

STEP 3 — Classify or Stratify

Classify the patient as a candidate for a DHEA replacement trial if she is a woman with PAI, has low libido, depressive symptoms, and/or low energy levels, and is on otherwise optimized glucocorticoid and mineralocorticoid therapy; proceed to step 4 to initiate the trial.

STEP 4 — Decide

Initiate a trial of DHEA 25–50 mg orally each morning, measure morning serum DHEAS before each dose aiming for the mid-normal range, and schedule clinical reassessment of libido, mood, and energy after 6 months; if sustained benefit is reported, continue therapy, otherwise discontinue DHEA.

Clinical Guardrails / Mimics / Pitfalls

Do not use DHEA as first-line therapy before optimizing glucocorticoid and mineralocorticoid replacement; avoid in men, pregnancy, or hormone-sensitive malignancies; monitor for androgenic side effects (acne, hirsutism, voice changes); do not rely solely on DHEAS levels without clinical response; DHEA is not routinely recommended due to insufficient evidence for broad use.

Concrete Clinical Example

A 48-year-old woman with autoimmune PAI on hydrocortisone 20 mg daily and fludrocortisone 100 µg daily reports persistent low libido and fatigue despite stable weight, normal BP, and normal electrolytes; after confirming optimized replacement, a trial of DHEA 25 mg each morning is started; at 6‑month follow‑up she notes improved energy and libido, DHEAS is mid‑normal, and therapy is continued.

Source: Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, DOI:10.1210/jc.2015-1710

---name: enda-dhea-trial-women-symptomsdescription: Suggests a trial of dehydroepiandrosterone (DHEA) replacement in women with primary adrenal insufficiency (PAI) who report low libido, depressive symptoms, and/or low energy levels despite otherwise optimized glucocorticoid and mineralocorticoid replacement. Consider when a woman with PAI presents with persistent low libido, depressive symptoms, and/or low energy levels after glucocorticoid and mineralocorticoid doses have been titrated to clinical targets.---# Trial DHEA Replacement in Women with PAI and Specific Symptoms## STEP 1 — Gather InformationConfirm PAI diagnosis, review current glucocorticoid (e.g., hydrocortisone 15–25 mg/day) and mineralocorticoid (fludrocortisone 50–100 µg/day) doses, assess for clinical signs of over- or under-replacement (weight, BP, electrolytes), and document presence of low libido, depressive symptoms, and/or low energy levels.## STEP 2 — Rule In / Rule OutDetermine whether symptoms persist despite optimized steroid replacement; if yes, proceed to DHEA trial consideration, otherwise evaluate for other causes of fatigue or low libido (e.g., thyroid dysfunction, depression, anemia).## STEP 3 — Classify or StratifyClassify the patient as a candidate for a DHEA replacement trial if she is a woman with PAI, has low libido, depressive symptoms, and/or low energy levels, and is on otherwise optimized glucocorticoid and mineralocorticoid therapy; proceed to step 4 to initiate the trial.## STEP 4 — DecideInitiate a trial of DHEA 25–50 mg orally each morning, measure morning serum DHEAS before each dose aiming for the mid-normal range, and schedule clinical reassessment of libido, mood, and energy after 6 months; if sustained benefit is reported, continue therapy, otherwise discontinue DHEA.## Clinical Guardrails / Mimics / PitfallsDo not use DHEA as first-line therapy before optimizing glucocorticoid and mineralocorticoid replacement; avoid in men, pregnancy, or hormone-sensitive malignancies; monitor for androgenic side effects (acne, hirsutism, voice changes); do not rely solely on DHEAS levels without clinical response; DHEA is not routinely recommended due to insufficient evidence for broad use.## Concrete Clinical ExampleA 48-year-old woman with autoimmune PAI on hydrocortisone 20 mg daily and fludrocortisone 100 µg daily reports persistent low libido and fatigue despite stable weight, normal BP, and normal electrolytes; after confirming optimized replacement, a trial of DHEA 25 mg each morning is started; at 6‑month follow‑up she notes improved energy and libido, DHEAS is mid‑normal, and therapy is continued.**Source:** Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, DOI:10.1210/jc.2015-1710

Frequently asked questions